SCYX Scynexis Inc

By Chris Wack

Scynexis Inc. said it has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Co., a biopharmaceutical company based in China.

Under the terms of the agreement, Hansoh will obtain an exclusive license from Scynexis to research, develop and commercialize ibrexafungerp in the greater China region.

Ibrexafungerp is an antifungal agent currently under review by the U.S. Food and Drug Administration for the treatment of vaginal yeast infections, and in late-stage development for multiple indications, including life-threatening fungal infections in hospitalized patients.

Under the terms of the agreement, Hansoh will be responsible for the development, regulatory approval and commercialization of ibrexafungerp in greater China. Scynexis will receive a $10 million upfront payment and will also be eligible to receive up to $112 million in development and commercial milestones, plus low double-digit royalties on net product sales.

Scynexis shares were up 15% to $10.91 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 17, 2021 08:41 ET (13:41 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.